CA
GENE

Cetera Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Cetera Advisors’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,792
Closed -$16.2K – 1786
2023
Q1 		$16.2K Hold
2,792
– – ﹤0.01% 1627
2022
Q4 		$13K Hold
2,792
– – ﹤0.01% 1580
2022
Q3 		$16K Sell
2,792
-600
-18% -$4.38K ﹤0.01% 1255
2022
Q2 		$20K Buy
3,392
+600
+21% +$4.34K ﹤0.01% 1343
2022
Q1 		$28K Sell
2,792
-1,200
-30% -$11.7K ﹤0.01% 1378
2021
Q4 		$38K Buy
+3,992
New +$51.2K ﹤0.01% 1410

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SA
Scarborough Advisors Annapolis, Maryland $914M AUM 17.4% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NC
NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cetera Advisors's GENE Position: Q2 2023 in Review

Cetera Advisors sold out of Genetic Technologies Ltd. (GENE) in Q2 2023, closing a stake of 2,792 shares — an estimated $16.2K sold.

Cetera Advisors first reported a position in GENE in Q4 2021 and held it in 6 quarters. The position peaked at $38K in Q4 2021. 11 funds tracked by Wall St. Rank hold GENE as of Q2 2023.

  • Cetera Advisors reported no remaining Genetic Technologies Ltd. position as of Q2 2023 after selling out during the quarter.
  • Cetera Advisors sold 2,792 Genetic Technologies Ltd. shares in Q2 2023, an estimated $16.2K.
  • Cetera Advisors first reported a position in Genetic Technologies Ltd. in Q4 2021 and held it in 6 quarters.
  • Cetera Advisors's Genetic Technologies Ltd. position peaked at $38K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q2 2023.

Based on Cetera Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.